Goldman Sachs analyst Salveen Richter maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of $9.00. The company's shares closed last Monday at $7.46, close to its 52-week low of $6.43. According to TipRanks.com, Richter is a 5-star analyst with an average return of 30.6% and a 52.2% success rate. Richter covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Vertex Pharmaceuticals, and Crispr Therapeutics AG. Currently, the analyst consensus on Allogene Therapeutics is a Strong Buy with an average price target of $21.50. See Insiders’ Hot Stocks on TipRanks >> Allogene Therapeutics' market cap is currently $1.
https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-a-hold-rating-on-allogene-therapeutics-allo?utm_source=advfn.com&utm_medium=referral
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Allogene Therapeutics Charts.
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Allogene Therapeutics Charts.